Skip to content
ClinCalc Pro
Menu
Topical anti-acne (oxidising / antibacterial / keratolytic) Pregnancy: Should only be used by a pregnant woman if clearly needed. Animal data show no safety concern for teratogenicity, embryotoxicity or peri-/post-natal development from cutaneously applied benzoyl peroxide, and no such association has arisen in widespread clinical use at concentrations up to 10% w/w. Breast-feeding: it is unknown whether benzoyl peroxide/metabolites are excreted in human milk and a risk to newborns/infants cannot be excluded — exercise caution and do not apply the preparation on the chest, to avoid accidental transfer to the infant.

Benzoyl peroxide

Brand names: Acnecide, PanOxyl, Epiduo (with adapalene), Duac (with clindamycin)

Benzoyl peroxide is a topical keratolytic and antibacterial agent widely used for mild-to-moderate acne vulgaris.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Apply a thin layer of the gel to the affected areas; the skin should be cleaned and dried before each application
Route: Topical — external (dermatological) use only
Frequency: Once daily, or as directed
Fetched UK SPC is Acnecide 10% w/w Gel (eMC product 101268). §4.2 states the indication population as adults and adolescents aged 12 years and over. It is recommended to initiate treatment with benzoyl peroxide 2.5% or 5% gel; if adequate results are not achieved with the 5% gel and the 5% gel is well tolerated, treatment with benzoyl peroxide 10% gel may be started. The extent of any drying or peeling may be adjusted by modifying the dosage schedule. Paediatric population: the safety and efficacy of Acnecide 10% w/w Gel in children aged less than 12 years have not been established — no per-kg or age-banded paediatric dose is given, so verify any under-18 use against a children's formulary. §4.4 cautions: may cause swelling and blistering of the skin (discontinue if these occur); a mild burning sensation is likely on first application, with reddening and peeling within a few days and a sudden increase in peeling in most patients during the first weeks — normally subsides within a day or two if treatment is temporarily discontinued; if severe irritation occurs use less frequently, temporarily discontinue, or discontinue altogether; excessive application will not improve efficacy but may increase irritation; use concomitant topical acne therapy with caution because of possible cumulative irritancy, especially with peeling, desquamating or abrasive agents; avoid contact with the eyes, mouth, angles of the nose and mucous membranes (if it enters the eye, wash thoroughly with water); caution when applying to the neck and other sensitive areas; do not apply on damaged skin because of the risk of sensitisation; may cause increased sensitivity to sunlight — avoid sunlamps and prolonged sun/UV exposure and use SPF 30 or higher with UVA protection plus protective clothing when strong sunlight cannot be avoided; contact with any coloured material including hair and dyed fabrics may result in bleaching or discoloration. Contains 40 mg propylene glycol (E1520) per gram (4.0% w/w), which may cause skin irritation. §4.2 does not state a maximum dose. The US label fetched as fallback (Dr. Zenovia Acne Cleanser, a wash-off cleanser) is a different product type and was not used.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

Side effects

  • Dry skin, erythema, skin exfoliation (peeling) and skin burning sensation — very common (≥1/10)
  • Pruritus — common (≥1/100 to <1/10)
  • Pain of skin (pain, stinging) — common
  • Skin irritation (irritant contact dermatitis) — common
  • Allergic contact dermatitis — uncommon (≥1/1,000 to <1/100)
  • Swelling of the face and allergic reactions, including application site hypersensitivity and anaphylaxis — reported post-marketing, frequency not known

Interactions

  • No interaction studies have been performed; however, drugs with desquamative, irritant and drying effects should not be used concurrently with benzoyl peroxide gel (SPC §4.5)

Clinical monograph

How it works

It releases reactive oxygen species that are bactericidal against Cutibacterium acnes, with additional keratolytic and comedolytic effects and no associated bacterial resistance.

Prescribing in practice

  • It bleaches hair and dyed fabrics, so warn patients to avoid contact with clothing, towels, bedding and hair.
  • Skin irritation, dryness and peeling are common, so start at a lower strength or reduced frequency if poorly tolerated.
  • Avoid contact with the eyes, lips and mucous membranes.

Monitoring

No laboratory monitoring is required; assess skin tolerability and acne response clinically.

Counselling the patient

  • It can bleach coloured clothing, towels, bedding and hair.
  • Some dryness, redness and peeling is expected, especially when starting.
  • Use sun protection, as skin may be more sensitive to sunlight.

Evidence & guidelines

NICE recommends benzoyl peroxide-containing regimens as first-line options for acne vulgaris.

Reference: SmPC Acnecide / Duac / Epiduo; NICE NG198 (Acne 2021); BAD Acne Guideline; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.